Ozempic vs Mounjaro 2026: Which Is Better for Diabetes & Weight Loss?
Reviewed against the SUSTAIN program (Ozempic), SURMOUNT program (Mounjaro/Zepbound), SURMOUNT-5 head-to-head (NEJM, May 2025), and current FDA labeling as of May 2026.
Both are FDA-approved for type 2 diabetes. Mounjaro produces dramatically more weight loss. Ozempic has more FDA indications and a new oral option.
The honest answer: If your primary goal is weight loss and you have T2D, Mounjaro (tirzepatide) is the stronger molecule. If you need the broadest range of FDA-approved protections (heart, kidneys, diabetes) or want an oral option, Ozempic (semaglutide) has more indications. Both are effective diabetes drugs. Insurance coverage is comparable for T2D use.
Ozempic vs Mounjaro: Head-to-Head At A Glance
| Factor | Ozempic | Mounjaro |
|---|---|---|
| Active ingredient | Semaglutide | Tirzepatide |
| Drug class | GLP-1 receptor agonist | Dual GLP-1 + GIP receptor agonist |
| Manufacturer | Novo Nordisk | Eli Lilly |
| FDA-approved for | T2D, CV risk reduction, CKD | T2D only |
| FDA-approved for weight loss? | No (Wegovy is the weight-loss brand) | No (Zepbound is the weight-loss brand) |
| Dose range | 0.5mg, 1mg, 2mg weekly injection | 2.5mg → 15mg weekly injection |
| Weight loss (own trials) | ~4-7% (SUSTAIN, secondary endpoint) | ~15-21% (SURMOUNT, primary endpoint) |
| Nausea rate (trials) | 16-20% | 17-22% |
| List price (May 2026) | ~$997-$1,027/mo | ~$1,080-$1,112/mo |
| Insurance copay with savings card | As low as $25/mo | As low as $25/mo |
| Oral formulation available? | Yes — new tablets May 4, 2026 (1.5/4/9mg) | No (injection only) |
| CV outcome data | SUSTAIN-6 + SELECT (via Wegovy) | SURPASS-CVOT pending |
| Supply status (May 2026) | Shortage resolved early 2025 | Shortage resolved late 2024 |
Sources: SUSTAIN program (NEJM, 2016-2022), SURMOUNT-5 (NEJM, May 2025), SURMOUNT-1 (NEJM, 2022), FDA labels (May 2026), manufacturer pricing pages.
The Critical Distinction: Both Are Diabetes Drugs
Unlike the Wegovy vs Mounjaro or Zepbound vs Wegovy comparisons, this is a diabetes-drug-vs-diabetes-drug matchup. Neither Ozempic nor Mounjaro is FDA-approved for weight loss. Their weight-loss counterparts are separate products:
Ozempic (semaglutide)
- FDA: Type 2 diabetes
- FDA: CV risk reduction (SUSTAIN-6)
- FDA: CKD/kidney protection (Jan 2025)
- New oral tablets launched May 4, 2026
- Weight-loss version: Wegovy (same molecule, higher dose up to 2.4mg)
Mounjaro (tirzepatide)
- FDA: Type 2 diabetes only (May 2022)
- CV outcome trial (SURPASS-CVOT) still pending
- No kidney/CKD indication yet
- Injection only (no oral formulation)
- Weight-loss version: Zepbound (same molecule, weight-loss label)
Why the SURMOUNT-5 comparison needs context
The SURMOUNT-5 head-to-head trial (NEJM, May 2025) compared tirzepatide at 10-15mg vs semaglutide at 1.7-2.4mg (Wegovy doses), not at Ozempic’s max dose of 2mg. If you are on Ozempic 0.5-2mg for diabetes, your weight-loss results will be lower than the -13.7% shown in SURMOUNT-5, because that trial used higher doses. Ozempic’s own SUSTAIN program showed 4-7% weight loss at approved doses — still meaningful, but not in the same range as the obesity-focused trials.
How They Work: One Receptor vs Two
Ozempic — GLP-1 only
Semaglutide activates the GLP-1 receptor. This slows gastric emptying, enhances glucose-dependent insulin secretion, suppresses glucagon, and reduces appetite. Effective for blood sugar control and produces moderate weight loss as a secondary benefit.
Mounjaro — dual GLP-1 + GIP
Tirzepatide activates two receptors: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). The dual mechanism amplifies insulin secretion, further suppresses appetite, and may improve fat oxidation. This explains the substantially greater weight loss seen in clinical trials compared to GLP-1-only drugs.
Weight Loss: SUSTAIN vs SURMOUNT
The weight-loss gap between these two drugs is substantial, but the context matters. Ozempic’s SUSTAIN trials measured weight loss as a secondary endpoint in T2D patients. Mounjaro’s SURMOUNT trials were designed for obesity and measured weight loss as the primary endpoint.
Ozempic (SUSTAIN program)
T2D patients, weight loss was secondary
- 0.5mg: ~3-4 kg (~4% of body weight)
- 1mg: ~4.5-6 kg (~5-7% of body weight)
- 2mg: ~6-7 kg (additional ~1 kg vs 1mg)
Source: SUSTAIN-1 through SUSTAIN-6 (NEJM, 2016-2022). Baseline weight ~90-95 kg.
Mounjaro (SURMOUNT program)
Obesity patients, weight loss was primary
- 5mg: -15.0% body weight
- 10mg: -19.5% body weight
- 15mg: -20.9% body weight
Source: SURMOUNT-1 (NEJM, June 2022). 72-week duration.
SURMOUNT-5: The definitive head-to-head
In the SURMOUNT-5 trial (NEJM, May 2025), tirzepatide at max tolerated doses (10-15mg) produced -20.2% weight loss vs semaglutide at 1.7-2.4mg (Wegovy doses) which produced -13.7% over 72 weeks (P<0.001). This confirms tirzepatide’s superiority even when semaglutide is dosed at its highest approved levels for weight loss — above what Ozempic delivers.
Side Effects: Comparable Overall
Unlike the Wegovy-dose comparisons where semaglutide shows significantly higher nausea rates (~44%), Ozempic at its lower T2D doses has a milder side-effect profile. The comparison with Mounjaro is closer than most people expect.
| Side Effect | Ozempic (SUSTAIN) | Mounjaro (SURMOUNT/SURPASS) |
|---|---|---|
| Nausea | 16-20% | 17-22% |
| Diarrhea | ~9% | 12-17% |
| Vomiting | 5-9% | ~5-10% |
| Constipation | 3-5% | Similar range |
| Discontinuation due to GI events | ~3-7% | ~3-7% |
Sources: SUSTAIN program (NEJM, 2016-2022) for Ozempic; SURMOUNT-1 (NEJM, 2022) and SURPASS-2 (NEJM, 2021) for Mounjaro. Side-effect rates are lower at Ozempic doses than at Wegovy doses because the max dose is lower (2mg vs 2.4mg).
Cost Comparison: May 2026 Pricing
- List price: ~$997-$1,027/month (injectable)
- With insurance + savings card: As low as $25/month
- Self-pay savings: $199/mo first 2 fills, then $349-$499/mo by dose
- New oral tablets: Pricing TBD (launched May 4, 2026)
- Generic: Tentative approval for injectable in 2026
- List price: ~$1,080-$1,112/month
- With insurance + savings card: As low as $25/month
- Self-pay savings: $150-$450/fill max savings via LillyDirect
- No oral formulation
- No generic expected near-term
Insurance coverage for T2D is strong for both
Since both Ozempic and Mounjaro are FDA-approved for type 2 diabetes, they typically receive Tier 2-3 formulary placement with commercial insurance. Prior authorization is common but usually straightforward for T2D. The new Medicare GLP-1 Bridge program (July 2026-Dec 2027) offers a $50 flat copay for eligible seniors on approved weight-loss GLP-1s, but T2D versions like Ozempic and Mounjaro are already covered under Part D for diabetes indications.
Off-Label Ozempic for Weight Loss: The Elephant in the Room
A significant portion of people comparing Ozempic to Mounjaro are actually interested in weight loss, not diabetes management. The reality: 20-40% of Ozempic prescriptions have historically been written off-label for weight loss, particularly during the 2023-2024 Wegovy shortage.
If weight loss is your primary goal
You should be comparing Wegovy vs Zepbound (the weight-loss versions), not Ozempic vs Mounjaro. Ozempic maxes out at 2mg; Wegovy goes to 2.4mg (with a new 7.2mg dose approved March 2026). Mounjaro is prescribed off-label for weight loss, but Zepbound (same molecule) has the explicit FDA approval. By 2026, Wegovy and Zepbound shortages have resolved, so the supply-driven reason for using T2D versions off-label is largely gone.
Which One Is Right For You?
Pick Ozempic if…
- You have T2D and want the broadest FDA protections (diabetes + heart + kidneys)
- You prefer an oral tablet option (new May 2026 Ozempic tablets)
- Your insurance formulary favors Ozempic over Mounjaro
- You want the slightly lower list price (~$997 vs ~$1,080)
- Moderate weight loss (4-7%) alongside diabetes control is sufficient
Pick Mounjaro if…
- You have T2D and want the maximum weight loss alongside diabetes control
- You have tried Ozempic and plateaued on weight loss
- Your prescriber recommends the dual GLP-1/GIP mechanism for your profile
- You are comfortable with injection-only administration
- You want access to higher doses (up to 15mg vs Ozempic max 2mg)
This is informational guidance, not medical advice. Your endocrinologist or prescriber will consider A1C levels, kidney function, cardiovascular risk, current medications, and your weight-loss goals before recommending one over the other.
Where to Get Ozempic or Mounjaro via Telehealth
The telehealth providers below prescribe both semaglutide and tirzepatide. Pricing verified May 2026.
Telehealth Providers Offering Ozempic or Mounjaro
Pricing accurate as of May 2026. Click a provider to see current pricing and start a consultation. We may earn a commission — at no extra cost to you. See our affiliate disclosure.
| Provider | Monthly Price | Rating | Action |
|---|---|---|---|
SkinnyRxBest Overall 503A compounded GLP-1 specialistCompounded Tirzepatide + Semaglutide (503A pharmacy) | $199–$399 | ★★★★★4.9 | View Best Offer |
TrimRx Online weight loss program with GLP-1 medicationGLP-1 weight loss program (catalog VERIFY) | From $179/mo | ★★★★☆4.5 | View Best Offer |
MEDViEditor’s Pick Reliable mid-tier compounded GLP-1Compounded Tirzepatide + Semaglutide | $179–$299 | ★★★★☆4.6 | View Best Offer |
DirectMedsBest for Sublingual Sublingual + injectable compounded GLP-1Compounded Sema + Tirz (injectable + sublingual), Sermorelin, NAD+, Epithalon | $179–$399 | ★★★★☆4.5 | View Best Offer |
Ivim HealthBest for Microdosing 360 wellness — branded + compounded + microdosing GLP-1Compounded Sema/Tirz/Liraglutide, microdosing GLP-1, Wegovy/Zepbound/Mounjaro/Ozempic/Saxenda, Wegovy Pill | From $75/mo + $74.99 program fee | ★★★★☆4.7 | View Best Offer |
Eden HealthBest Value Branded + compounded with intro pricingCompounded Sema + Tirz, branded GLP-1, NAD+ (5 formats), Sermorelin, hormone therapy | $149 intro / $229–$249 ongoing | ★★★★☆4.7 | View Best Offer |
Sprout Health PENDING — URL not yet confirmedVERIFY | VERIFY | ☆☆☆☆☆0.0 | View Best Offer |
Elevate Health 3-month tirzepatide starter programCompounded Tirzepatide (2.5–15 mg/wk titration), Compounded Semaglutide | $299/mo or $897/3-mo bundle | ★★★★☆4.4 | View Best Offer |
OrderlyMeds Personalized GLP-1 + $3,700 value bundleCompounded Tirzepatide + Semaglutide, Wegovy, Zepbound | $149–$299 compounded, $1,498–$1,839 branded | ★★★★☆4.5 | View Best Offer |
GobyMeds Compounded GLP-1 with B12/NAD+ stack add-onsCompounded Sema + Tirz with B12/B6/NAD+/glycine combos, Wegovy, Zepbound, Sermorelin, NAD+ | From $99/mo (compounded sema) | ★★★★☆4.6 | View Best Offer |
Ro Largest US telehealth platformBranded (Wegovy, Zepbound) + select compounded | $149/mo + meds | ★★★★☆4.6 | View Best Offer |
Calibrate Coaching-led metabolic programBranded GLP-1s + 1:1 coaching + labs | $199/mo (3-month minimum) | ★★★★☆4.3 | View Best Offer |
Found Insurance-first weight-care platformBranded (insurance-billed) + compounded | ~$129/mo + meds | ★★★★☆4.2 | View Best Offer |
EmbodyBest Overall Flat $299/mo refills + GLP-1 gum (needle-free)Compounded Semaglutide + Tirzepatide (injectable + GLP-1 gum) | $149 first month / $299 flat refills | ★★★★★4.7 | View Best Offer |
Gala HealthBest for 3-Month Bundles All-inclusive 3-month GLP-1 bundles from $179–$199/moCompounded Semaglutide or Tirzepatide (GLP-1/GIP) | $179–$199/mo (3-month plan) | ★★★★☆4.5 | View Best Offer |
Care Bare RxBest Multi-Vertical Weight loss + hair + sexual health + NAD+ — discreet multi-careCompounded Semaglutide + Tirzepatide (oral + injectable) + hair + sexual health + NAD+ | From $199/mo (weight loss) | ★★★★☆4.4 | View Best Offer |
System LabsBest Value Lowest GLP-1 entry ($179/mo) + longevity stack — NAD+, B-12, sermorelinCompounded GLP-1 + NAD+ + B-12 + Sermorelin (oral + injectable) | GLP-1 $179/mo (lowest entry) | ★★★★☆4.5 | View Best Offer |
Strut Health No-video telehealth — GLP-1, hair, skin, ED + 2-day shippingCompounded Semaglutide + Tirzepatide, Hair Loss, Oral Sermorelin, Skin Care, ED | Oral Semaglutide from $99/mo, Oral Tirzepatide from $199/mo | ★★★★☆4.6 | View Best Offer |
TMatesBest Overall $158-$249/mo semaglutide, $167-$297/mo tirzepatide — same price all dosesCompounded Semaglutide + Tirzepatide (GLP-1), NAD+, TRT, ED, Skin Care, Hair Loss | Semaglutide $158-$249/mo, Tirzepatide $167-$297/mo (1-12 mo plans) | ★★★★☆4.7 | View Best Offer |
Pricing and availability current as of May 2026. We earn a commission if you sign up through our links — at no additional cost to you. See our methodology for how we evaluate providers.
Frequently Asked Questions
Is Ozempic the same as Mounjaro?+
No. Ozempic contains semaglutide (a GLP-1 receptor agonist made by Novo Nordisk), while Mounjaro contains tirzepatide (a dual GLP-1 + GIP receptor agonist made by Eli Lilly). They are different molecules from different manufacturers with different mechanisms of action. Both are FDA-approved for type 2 diabetes but are not interchangeable.
Which causes more weight loss, Ozempic or Mounjaro?+
Mounjaro causes significantly more weight loss. In the SURMOUNT-5 head-to-head trial (NEJM, May 2025), tirzepatide (Mounjaro's molecule) at max doses produced -20.2% weight loss vs semaglutide's -13.7% over 72 weeks. Note: this trial used Wegovy-level doses (2.4mg semaglutide), not the lower Ozempic doses (max 2mg). Ozempic at its approved doses produces more modest weight loss of approximately 4-7% in SUSTAIN trials, as weight loss was only a secondary endpoint.
Can you use Ozempic for weight loss?+
Ozempic is FDA-approved only for type 2 diabetes, not weight loss. However, 20-40% of Ozempic prescriptions have historically been written off-label for weight loss. If you want semaglutide specifically for weight loss, Wegovy (same molecule, higher dose of 2.4mg) is the FDA-approved option. By 2026, off-label Ozempic use for weight loss is declining as Wegovy availability has improved.
How much does Ozempic cost vs Mounjaro in 2026?+
As of May 2026: Ozempic list price is approximately $997-$1,027 per month. Mounjaro list price is approximately $1,080-$1,112 per month. Both offer manufacturer savings cards: with commercial insurance, copays as low as $25/month for either drug. Self-pay: Ozempic offers $199/month for first 2 fills, then $349-$499/month depending on dose. Mounjaro has comparable self-pay savings. Overall, Ozempic is roughly 5-10% cheaper at list price.
Does insurance cover Ozempic and Mounjaro?+
Yes, both are generally well-covered for type 2 diabetes. Since both are FDA-approved for T2D, they typically receive Tier 2-3 formulary placement with lower copays and easier prior authorization. Coverage for weight loss is more restrictive — if you want GLP-1s for weight loss, you would need the weight-loss branded versions (Wegovy for semaglutide, Zepbound for tirzepatide), which face higher copays and stricter requirements. A new Medicare GLP-1 Bridge program (July 2026-Dec 2027) offers a $50 flat copay for eligible seniors.
What are the side effects of Ozempic vs Mounjaro?+
Both cause primarily GI side effects. Ozempic (from SUSTAIN trials): nausea 16-20%, diarrhea ~9%, vomiting 5-9%, constipation 3-5%. Mounjaro (from SURMOUNT/SURPASS trials): nausea 17-22%, diarrhea 12-17%, vomiting ~5-10%. Discontinuation rates due to GI events are low for both (~3-7%). The main difference: Mounjaro tends to cause slightly more diarrhea, while rates are otherwise comparable. Both improve with slow dose titration.
Related Comparison Guides
Editorial note: This page is reviewed against primary sources: SUSTAIN program (NEJM, 2016-2022), SURMOUNT-1 (NEJM, 2022), SURMOUNT-5 (NEJM, May 2025), and current FDA labeling. Pricing verified May 3, 2026 from manufacturer pricing pages, NovoCare, and GoodRx. FDA approval dates and indications verified against FDA.gov drug labels.
Not medical advice. Always consult a licensed prescriber before starting, switching, or stopping any GLP-1 medication.
Related Guides
How this page is reviewed
Editorially reviewed by GLP1CompareHub Editorial Team. We are an independent affiliate publisher — we are not licensed medical providers and this site does not deliver medical advice. Every claim on this page is sourced to a verifiable origin (peer-reviewed study, FDA documentation, live brand-site crawl, or our Katalys partner dashboard).
Affiliate disclosure: We earn a commission when you sign up with a provider through our links — at no extra cost to you. We do not rank providers by what they pay us; we rank by patient fit. Full disclosure. Read our methodology · medical disclaimer.
Related Guides
Continue your research with these related independent reviews.